中文摘要：

目的系统评价参麦注射液对急性心肌梗死（AMI）病死率的影响。方法根据系统评价要求制定相应的详细的纳入与排除标准,按拟定的标准制定出系统、全面的检索策略。计算机检索Cochrane数据库、PubMed、OVID、CBM、CNKI、CMCC等,手工检索国内心血管疾病和中医药期刊以及会议论文集,筛选参麦注射液治疗AMI的随机对照试验（RCT）或半随机对照试验。采用Cochrane handbook for systematic reviews of interventions 4.2.6中推荐的简单评估法进行质量分级,应用RevMan 4.2.2统计软件进行Meta分析。结果共纳入13个RCT的1 707例AMI患者,纳入研究的文献质量均为C级。Meta分析结果显示,参麦注射液治疗组较对照组的病死率降低（总效应Z=3.58,P=0.000 3）。结论根据当前证据,参麦注射液可以显著降低AMI病死率。由于纳入研究的文献质量较低,且存在一定的发表偏倚,从这些研究中所获得的证据强度不高,需要更高质量的研究加以验证。

英文摘要：

Objective It is to systematically evaluate the therapeutic efficacy of Shenmai injection（SMI） on the mortality rate of patients with acute myocardial infarction（AMI）.Methods According to the requisition of systematic evaluation,standardization of the inclusion and exclusion criteria was formulated in detail,and a systematic,comprehensive search strategy according to laying standardization was developped.Random controlled test（RCT） or half RCT about the treatment for AMI with SMI were retrieved by computerized searching from Cochrane Central Register of Controlled Trials,PubMed,OVID,CBM,CNKI,CMCC,and those in Chinese Conference Treatises and Periodal in cardiovascular disease were handed searched.Quality of them was evaluated with the method recommended in Cochrane Reviewer＇s Handbook 4.2.6.Statistical analysis was performed using the Cochrane Collaboration＇s Rev Man 4.2.2 software.Results 13 RCT（conducted in China）,involving 1707 AMI patients meeting the inclusion criteria were identified.The quality of all the literature chosen was C degree.The results of meta-analysis indicated that the mortality rate of SMI treatment group wan lower than that of control group（total effect：Z=3.58,P=0.0003）.Conclusion Current evidences show that SMI can significantly decrease the mortality rate of AMI.As the evidence obtained is not strong enough owing to the publication bias and rather poor quality of current studies enclosed,further studies with high-quality,large-scale trials are required for identification.